|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Tom DiLenge |
Date | 4/22/2019 7:41:10 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
Biomass Programs (Non-Funding)
---Implementation of the Agriculture Improvement Act of 2018
EPA Regulations on Biotechnology
---Efficient Science-Based Reviews of Biotech Products
---Regulatory Treatment of Gene Edited Products
---S.483: Pesticide Registration Improvement Extension Act of 2018
Foreign Agricultural Biotechnology Laws and Regulations
---Asynchronous Approvals
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
---Japan Biotechnology Regulations
---Korea Biotechnology Regulations
---Like-minded Countries Initiatives
Funding for Biomass Crop Assistance Program
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Genetically Engineered (GE) Animals
---Amendment on GE Salmon Labeling
---Amendment to restrict FDA Approval of GE Salmon
---Efficient Science-Based Review of Biotech Products
---FDA Approval
---FDA Proposed Guidance on Gene Editing
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Labeling
Genetically Engineered (GE) Plants
---FDA Proposed Guidance on Gene Editing
Review and Labeling of Food Derived from Biotechnology
---Implementation of Disclosure Law
USDA/APHIS Agricultural Biotechnology Regulations
---Efficient Science-Based Review of Biotech Products
---Potential Revisions to Part 340 Regulations
---Regulatory Treatment of Gene Edited Products
The United States-Mexico-Canada Agreement
---Ag-Biotech Provisions
US-EU Trade Agreement
---Ag-Biotech Provisions
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), U.S. Trade Representative (USTR), White House Office, Environmental Protection Agency (EPA), State - Dept of (DOS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Matthew |
OMara |
|
|
|
Joseph |
Damond |
|
|
|
Michael |
Mattoon |
|
|
|
Andrew |
Connor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Genetically Engineered (GE) Animals
---Amendment on GE Salmon Labeling
---Amendment to restrict FDA Approval of GE Salmon
---Efficient Science-Based Review of Biotech Products
---FDA Approval
---FDA Proposed Guidance on Gene Editing
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Labeling
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Dana |
O'Brien |
|
|
|
Michael |
Mattoon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Funding for Antimicrobial Resistance Programs
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Funding for Biofuels
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Energy and Water Development and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
---Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
---Interior, Environment and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Funding for Biomass Crop Assistance Program
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Funding for Biorefineries
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
---Interior, Environment and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Funding for National Institutes of Health
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Funding for Renewable Chemicals/Bio-based Products
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
---Energy and Water Development and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Phyllis |
Arthur |
|
|
|
Kyle |
Kunkler |
|
|
|
Michael |
Mattoon |
|
|
|
Thomas |
Brunet |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CHM
16. Specific lobbying issues
Funding for Renewable Chemicals/Bio-based Products
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
---Energy and Water Development and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Renewable Chemicals/Bio-based Products (Non-Funding)
---Implementation of the Agriculture Improvement Act of 2018
---Investment Tax Credit
---Master Limited Partnership Parity Act (Discussion Draft Senate)
---Production Tax Credit
---H.R.2051/S.999: Sustainable Chemistry Research and Development Act of 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Michael |
Mattoon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Bayh-Dole Act/Tech Transfer
---March-In Rights
Compulsory Licensing
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.465/S.102: Prescription Drug Price Relief Act of 2019
Intellectual Property International Enforcement
---Compulsory Licensing
---China
---India
---Malaysia
Inter Partes Review
---Implementation of the America Invents Act of 2011
---H.R. 990/S.344 Hatch-Waxman Integrity Act of 2019
---STRONGER Patents Act (Discussion Draft House/Senate)
Diversity in Patenting
Drug Patent Settlements
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---H.R.1188/S.366: Forcing Limits on Abusive and Tumultuous Prices (FLAT) Prices Act
Foreign Drug Data Protection Laws
---China
Patenting of Biological Inventions
---Argentina Biotech Patentability Guidelines
---DNA Patenting and Licensing
---PTO Examination Guidelines
---Section 101 Modernization
Patent Reform
---Patent Litigation Reform
---STRONGER Patents Act (Discussion Draft House/Senate)
The United States-Mexico-Canada Agreement
---IP Provisions
US-UK Trade Agreement
---IP Provisions
US-Japan Trade Agreement
---IP Provisions
US-EU Trade Agreement
---IP Provisions
World Trade Organization - Special 301 Submissions
---Canada
---China
---India
---Latin America
---Malaysia
---Middle East
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO), Health & Human Services - Dept of (HHS), White House Office, State - Dept of (DOS), Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
David |
Lachmann |
|
|
|
Hans |
Sauer |
|
|
|
Jeanne |
Haggerty |
|
|
|
Joseph |
Damond |
|
|
|
Melissa |
Brand |
|
|
|
Matthew |
OMara |
|
|
|
Michael |
Mattoon |
|
|
|
Hayley |
Alexander |
|
|
|
Shea |
Hartley |
|
|
|
Thomas |
Brunet |
|
|
|
Andrew |
Connor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Drug Importation
---General
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---S.97: Affordable and Safe Prescription Drug Importation Act of 2019
---S.844: Short on Competition Act of 2019
Genetically Engineered (GE) Animals
---Amendment on GE Salmon Labeling
---Amendment to restrict FDA Approval of GE Salmon
---Efficient Science-Based Review of Biotech Products
---FDA Approval
---FDA Proposed Guidance on Gene Editing
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Labeling
Opioid Crisis
---NIH Research
---Coverage and Reimbursement
---Implementation of the SUPPORT for Patients and Communities Act of 2018
Review and Labeling of Food Derived from Biotechnology
---Implementation of Disclosure Law
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Natl Institutes of Health (NIH), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cartier |
Esham |
|
|
|
Dana |
OBrien |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Jordan |
Layson |
|
|
|
Kyle |
Kunkler |
|
|
|
Shea |
Hartley |
|
|
|
Michael |
Mattoon |
|
|
|
Thomas |
Brunet |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Biofuels (Non-Funding)
---Advanced and Second Generation Biofuels Tax Entenders
---Implementation of the Agriculture Improvement Act of 2018
---Master Limited Partnership Parity Act (Discussion Draft Senate)
---Clean Energy for America Act (Discussion Draft Senate)
Biomass Programs (Non-Funding)
---Implementation of the Agriculture Improvement Act of 2018
Biorefineries (non-funding)
---Implementation of the Agriculture Improvement Act of 2018
Funding for Biofuels
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Energy and Water Development and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
---Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
---Interior, Environment and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Funding for Biomass Crop Assistance Program
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Funding for Biorefineries
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
---Interior, Environment and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Renewable Fuel Standard (RFS)
---RFS Reform
---Small Refinery Waivers
---Cellulosic Registration Applications for Corn Kernel Fiber
---E 15 EPA Implementation of RVP Waiver
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Michael |
Mattoon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Genetically Engineered (GE) Animals
---Amendment on GE Salmon Labeling
---Amendment to restrict FDA Approval of GE Salmon
---Efficient Science-Based Review of Biotech Products
---FDA Approval
---FDA Proposed Guidance on Gene Editing
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Labeling
Review and Labeling of Food Derived from Biotechnology
---Implementation of Disclosure Law
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Michael |
Mattoon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Biofuels (Non-Funding)
---Advanced and Second Generation Biofuels Tax Entenders
---Implementation of the Agriculture Improvement Act of 2018
---Master Limited Partnership Parity Act (Discussion Draft Senate)
---Clean Energy for America Act (Discussion Draft Senate)
Biomass Programs (Non-Funding)
---Implementation of the Agriculture Improvement Act of 2018
Biorefineries (non-funding)
---Implementation of the Agriculture Improvement Act of 2018
Funding for Biofuels
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Energy and Water Development and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
---Transportation, and Housing and Urban Development, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
---Interior, Environment and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Funding for Biomass Crop Assistance Program
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Funding for Biorefineries
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
---Interior, Environment and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Renewable Fuel Standard (RFS)
---RFS Reform
---Small Refinery Waivers
---Cellulosic Registration Applications for Corn Kernel Fiber
---E 15 EPA Implementation of RVP Waiver
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kyle |
Kunkler |
|
|
|
Michael |
Mattoon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
340B Drug Discount Program
---Program Implementation & Oversight
---340B Pause Act (Discussion Draft House/Senate)
---340B Optimization Act (Discussion Draft House/Senate)
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Access to Medicines/World Health Organization
Antibiotic & Diagnostic Tax Credit
Biodefense Research, Development and Procurement Issues (Non-funding)
---Implementation of the 21st Century Cures Act of 2016
---Tropical Disease Priority Review Voucher (PRV) Program
---Implementation of Medical Countermeasures Innovation Act
---Reauthorization of the Pandemic and All Hazards Preparedness Act
---H.R.269: Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
---National Biodefense Strategy
---Gene Editing
Biosimilars
---Access to Samples for Testing
---Implementation and Reauthorization of the Biosimilar User Fee Act of 2017
---Brazil Biologics Regulations
---Coding
---Naming
---H.R.965/S.340: CREATES Act of 2019
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.1520: Purple Book Continuity Act of 2019
---India Biologics Regulations
---Interchangeability and Pharmacy Substitution
---Mexico Biologics Regulations
---S.659: Biologic Patent Transparency Act of 2019
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
Drug Evaluation and Review
---H.R.1503: Orange Book Transparency Act of 2019
---Implementation of the Prescription Drug User Fee Act (PDUFA) VI
Drug Importation
---General
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---S. 97: Affordable and Safe Prescription Drug Importation Act of 2019
---S. 844: Short on Competition Act of 2019
Drug Manufacturing, Quality & Distribution
---Counterfeiting
---Drug Shortages
---Pharmacy Compounding & Oversight
---H.R.1959: Preserving Patient Access to Compounded Medications Act of 2019
---S.551: REFUND Act of 2019
---Supply Chain Integrity and Traceability
Drug Pricing
---General
---HHS Blueprint to lower drug prices and reduce out of pocket costs
---Pricing Transparency
---H.R.965/S.340: CREATES Act of 2019
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---H.R.1503: Orange Book Transparency Act of 2019
---H.R.2113: Prescription Drug STAR Act of 2019
---H.R.2069/S.474: Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019
---H.R.1093/S.378: Stop Price Gouging Act of 2019
---S.476: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019
---S.62: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
---S.99: Medicare Drug Price Negotiation Act of 2019
---S.97: Affordable and Safe Prescription Drug Importation Act of 2019
---S.844: Short on Competition Act of 2019
---H.R.1520: Purple Book Continuity Act of 2019
---H.R.1188/S.366: Forcing Limits on Abusive and Tumultuous Prices (FLAT) Prices Act
Foreign Drug Data Protection Laws
---China
Funding for Antimicrobial Resistance Programs
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Funding for National Institutes of Health
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Generic Drug Entry
---Access to Samples for Testing
---Generic Drug Application Review Reforms
---Incentives for Generic Drug Entry
---H.R.938: Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019
---H.R.965/S.340: CREATES Act of 2019
---H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019
---S.64: Preserve Access to Affordable Generics and Biosimilars Act of 2019
Medicare Expansion
---H.R.1384: Medicare for All Act of 2019
---S.1129: A bill to establish a Medicare-for-all national health insurance program of 2019
Medicaid
---Drug Benefit Design
---Pricing and Rebates
---Average Manufacturer Price Calculations
The United States-Mexico-Canada Agreement
---IP Provisions
US-UK Trade Agreement
---IP Provisions
US-EU Trade Agreement
---IP Provisions
US-Japan Trade Agreement
---IP Provisions
Opioid Crisis
---NIH Research
---Coverage and Reimbursement
---Implementation of the SUPPORT for Patients and Communities Act of 2018
Orphan Drug Issues
---Tax Credit
Reimbursement and Coverage of Innovative Products
---CMMI Authority
---HHS Blueprint to lower drug prices and reduce out of pocket costs
---International Pricing Index Proposal
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---Protected Classes
---Step Therapy
---Third Party Support of Patient Premiums and Cost-Sharing Obligations
---Value-based Contracting and Communications
---Administration Rebate Rule
---Surprise Billing
---H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019
---S.62: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
---S.99: Medicare Drug Price Negotiation Act of 2019
Trade and Foreign Drug Price Controls
Vaccines and Infectious Diseases
---Vaccine and Anti-Microbial Resistance Product Development and Incentives
---Vaccine Injury Compensation Program
---Vaccine Safety
---Adult Immunization Education
---Vaccine Quality Measure
Vaccine Injury Compensation Tax
---H.R.1973: Vaccine Access Improvement Act of 2019
---Reintroduction of the Vaccine Access Improvement Act in the Senate
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Natl Institutes of Health (NIH), White House Office, U.S. Trade Representative (USTR), Health & Human Services - Dept of (HHS), State - Dept of (DOS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Cartier |
Esham |
|
|
|
Charles |
Fritts |
|
|
|
David |
Lachmann |
|
|
|
Hayley |
Alexander |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeanne |
Haggerty |
|
|
|
Jordan |
Layson |
|
|
|
Joseph |
Damond |
|
|
|
Phyllis |
Arthur |
|
|
|
John |
Murphy |
|
|
|
Cameron |
Arterton |
|
|
|
Matt |
O'Mara |
|
|
|
Aiken |
Hackett |
|
|
|
Hans |
Sauer |
|
|
|
Shea |
Hartley |
|
|
|
Michael |
Mattoon |
|
|
|
Thomas |
Brunet |
|
|
|
Andrew |
Connor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Biodefense Research, Development and Procurement Issues (Non-funding)
---Implementation of the 21st Century Cures Act of 2016
---Tropical Disease Priority Review Voucher (PRV) Program
---Implementation of Medical Countermeasures Innovation Act
---Reauthorization of the Pandemic and All Hazards Preparedness Act
---H.R.269: Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
---National Biodefense Strategy
---Gene Editing
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Jordan |
Layson |
|
|
|
Phyllis |
Arthur |
|
|
|
Michael |
Mattoon |
|
|
|
Thomas |
Brunet |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Biodefense Research, Development and Procurement Issues (Non-funding)
---Implementation of the 21st Century Cures Act of 2016
---Tropical Disease Priority Review Voucher (PRV) Program
---Reauthorization of the Pandemic and All Hazards Preparedness Act
---Implementation of Medical Countermeasures Innovation Act
---H.R.269 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
---National Biodefense Strategy
---Gene Editing
Funding for Antimicrobial Resistance Programs
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
Funding for National Institutes of Health
---H.J.Res.31: Consolidated Appropriations Act for FY 2019
---Labor, Health and Human Services, Education, and Related Agencies Appropriations Act for FY 2020 (Discussion Draft House/Senate)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Jordan |
Layson |
|
|
|
Phyllis |
Arthur |
|
|
|
Michael |
Mattoon |
|
|
|
Thomas |
Brunet |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare Expansion
---H.R.1384: Medicare for All Act of 2019
---S.1129: A bill to establish a Medicare-for-all national health insurance program of 2019
Medicaid
---Drug Benefit Design
---Pricing and Rebates
---Average Manufacturer Price Calculation
Reimbursement and Coverage of Innovative Products
---CMMI Authority
---HHS Blueprint to lower drug prices and reduce out of pocket costs
---International Pricing Index Proposal
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---Protected Classes
---Step Therapy
---Third Party Support of Patient Premiums and Cost-Sharing Obligations
---Value-based Contracting and Communications
---Administration Rebate Rule
---Surprise Billing
---H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019
---S.62: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019
---S.99: Medicare Drug Price Negotiation Act of 2019
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Jordan |
Layson |
|
|
|
John |
Murphy |
|
|
|
David |
Lachmann |
|
|
|
Jamie |
Gregorian |
|
|
|
Aiken |
Hackett |
|
|
|
Michael |
Mattoon |
|
|
|
Thomas |
Brunet |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Proxy Advisory Services
---Corporate Governance Reform and Transparency
---Impact of Policies on Small Public Companies
Sarbanes Oxley Section 404 (b)
---Reintroduction of the Fostering Innovation Act in the House of Representatives
---S.452: Fostering Innovation Act of 2019
---Small Issuer Exemption
Short Selling Transparency
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Securities & Exchange Commission (SEC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Lachmann |
|
|
|
Jeanne |
Haggerty |
|
|
|
Cartier |
Esham |
|
|
|
Cameron |
Arterton |
|
|
|
Lisa |
Schaefer |
|
|
|
Michael |
Mattoon |
|
|
|
Charles |
Fritts |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Antibiotic & Diagnostic Tax Credit
Biofuels (Non-Funding)
---Advanced and Second Generation Biofuels Tax Entenders
---Master Limited Partnership Parity Act (Discussion Draft Senate)
Capital Formation Investment Incentives
---Reform of Net Operating Loss Rules
---Reintroduction of the American Innovation Act in the House
---Introduction of the American Innovation Act in the Senate
Orphan Drug Issues
---Tax Credit
Renewable Chemicals/Bio-based Products (Non-Funding)
---Investment Tax Credit
---Production Tax Credit
---Master Limited Partnership Parity Act (Discussion Draft Senate)
Qualified Small Business Stock (QSBS)
Research & Development Tax Credit Reforms
---Expensing of R&D Expenditures
---R&D Payroll Credit
Vaccine Injury Compensation Tax
---H.R.1973: Vaccine Access Improvement Act of 2019
---Reintroduction of the Vaccine Access Improvement Act in the Senate
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Commerce - Dept of (DOC), Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Cartier |
Esham |
|
|
|
Cameron |
Arteron |
|
|
|
Aiken |
Hackett |
|
|
|
Michael |
Mattoon |
|
|
|
Thomas |
Brunet |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Drug Importation
---General
---H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019
---S. 97: Affordable and Safe Prescription Drug Importation Act of 2019
---S. 844: Short on Competition Act of 2019
Foreign Agricultural Biotechnology Laws and Regulations
---Asynchronous Approvals
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
---Japan Biotechnology Regulations
---Korea Biotechnology Regulations
---Like-minded Countries Initiatives
Foreign Drug Data Protection Laws
---China
Intellectual Property International Enforcement
---Compulsory Licensing
---China
---Malaysia
---India
The United States-Mexico-Canada Agreement
---IP Provisions
---Ag-Biotech Provisions
Trade and Foreign Drug Price Controls
Committee on Foreign Investment in the United States (CFIUS)
---Foreign Investment Risk Review Modernization Act (FIRRMA) Implementation
US-UK Trade Agreement
---IP Provisions
US-EU Trade Agreement
---IP Provisions
---Ag-Biotech Provisions
US-Japan Trade Agreement
---IP Provisions
World Trade Organization - Special 301 Submissions
---Canada
---China
---India
---Latin America
---Malaysia
---Middle East
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR), Patent & Trademark Office (PTO), Treasury - Dept of, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
David |
Lachmann |
|
|
|
Jeanne |
Haggerty |
|
|
|
Jordan |
Layson |
|
|
|
Joseph |
Damond |
|
|
|
Matthew |
OMara |
|
|
|
Hans |
Sauer |
|
|
|
Kyle |
Kunkler |
|
|
|
Shea |
Hartley |
|
|
|
Michael |
Mattoon |
|
|
|
Cartier |
Esham |
|
|
|
Thomas |
Brunet |
|
|
|
Andrew |
Connor |
|
|
|
Cameron |
Arterton |
|
|
|
Lisa |
Schaefer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |